NO892941L - Monoklonalt antistoff mot den rgd-rettede adhesjonsreseptor paa endotelceller. - Google Patents

Monoklonalt antistoff mot den rgd-rettede adhesjonsreseptor paa endotelceller.

Info

Publication number: NO892941L
Authority: NO; Norway
Prior art keywords: ecr; cells; antibody; molecules; antibody molecules
Prior art date: 1987-11-19

Application number

NO89892941A

Other languages

English (en)

Norwegian (no)

Other versions

NO892941D0 (no

Inventor

David A Cheresh

Original Assignee

Scripps Clinic Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-19

Filing date

1989-07-18

Publication date

1989-09-15

1988-11-17 Priority claimed from PCT/US1988/004118 external-priority patent/WO1989005155A1/en

1989-07-18 Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res

1989-07-18 Publication of NO892941D0 publication Critical patent/NO892941D0/no

1989-09-15 Publication of NO892941L publication Critical patent/NO892941L/no

Links

239000000853 adhesive Substances 0.000 title description 2
230000001070 adhesive effect Effects 0.000 title description 2
238000000034 method Methods 0.000 claims abstract description 50
108010047303 von Willebrand Factor Proteins 0.000 claims abstract description 31
102100036537 von Willebrand factor Human genes 0.000 claims abstract description 31
229960001134 von willebrand factor Drugs 0.000 claims abstract description 31
108010049003 Fibrinogen Proteins 0.000 claims abstract description 30
102000008946 Fibrinogen Human genes 0.000 claims abstract description 30
229940012952 fibrinogen Drugs 0.000 claims abstract description 30
102100035140 Vitronectin Human genes 0.000 claims abstract description 29
108010031318 Vitronectin Proteins 0.000 claims abstract description 28
210000004027 cell Anatomy 0.000 claims description 204
210000004408 hybridoma Anatomy 0.000 claims description 59
230000036046 immunoreaction Effects 0.000 claims description 42
239000000203 mixture Substances 0.000 claims description 28
108010032595 Antibody Binding Sites Proteins 0.000 claims description 23
238000004458 analytical method Methods 0.000 claims description 23
238000001727 in vivo Methods 0.000 claims description 17
230000002401 inhibitory effect Effects 0.000 claims description 14
108060003951 Immunoglobulin Proteins 0.000 claims description 13
108010053299 glycyl-arginyl-glycyl-aspartyl-seryl-proline Proteins 0.000 claims description 13
102000018358 immunoglobulin Human genes 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 11
230000004614 tumor growth Effects 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
NTEDOEBWPRVVSG-FQUUOJAGSA-N (2s)-1-[(2r)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CO)C(=O)N1CCC[C@H]1C(O)=O NTEDOEBWPRVVSG-FQUUOJAGSA-N 0.000 claims 1
201000001441 melanoma Diseases 0.000 abstract description 16
102000019997 adhesion receptor Human genes 0.000 abstract description 13
108010013985 adhesion receptor Proteins 0.000 abstract description 13
239000011159 matrix material Substances 0.000 abstract description 8
230000003511 endothelial effect Effects 0.000 abstract description 6
102000004169 proteins and genes Human genes 0.000 description 49
108090000623 proteins and genes Proteins 0.000 description 49
239000000047 product Substances 0.000 description 34
238000002360 preparation method Methods 0.000 description 26
239000001963 growth medium Substances 0.000 description 24
229920002684 Sepharose Polymers 0.000 description 20
108091003079 Bovine Serum Albumin Proteins 0.000 description 19
239000000243 solution Substances 0.000 description 19
239000003153 chemical reaction reagent Substances 0.000 description 17
230000001419 dependent effect Effects 0.000 description 17
239000002953 phosphate buffered saline Substances 0.000 description 17
239000002243 precursor Substances 0.000 description 16
125000000539 amino acid group Chemical group 0.000 description 15
239000012894 fetal calf serum Substances 0.000 description 15
239000006166 lysate Substances 0.000 description 15
239000008188 pellet Substances 0.000 description 15
102100022337 Integrin alpha-V Human genes 0.000 description 14
108010048673 Vitronectin Receptors Proteins 0.000 description 14
239000000427 antigen Substances 0.000 description 14
108091007433 antigens Proteins 0.000 description 14
102000036639 antigens Human genes 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
239000000523 sample Substances 0.000 description 14
238000009739 binding Methods 0.000 description 13
239000000758 substrate Substances 0.000 description 13
238000003556 assay Methods 0.000 description 12
239000011324 bead Substances 0.000 description 12
230000027455 binding Effects 0.000 description 12
238000001114 immunoprecipitation Methods 0.000 description 12
108060003393 Granulin Proteins 0.000 description 11
210000002889 endothelial cell Anatomy 0.000 description 11
238000001514 detection method Methods 0.000 description 10
239000000499 gel Substances 0.000 description 10
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 9
239000002609 medium Substances 0.000 description 9
229960004452 methionine Drugs 0.000 description 9
230000009870 specific binding Effects 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000011230 binding agent Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000000284 extract Substances 0.000 description 8
239000003550 marker Substances 0.000 description 8
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
239000000833 heterodimer Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
241000894007 species Species 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
108010018907 Gly-Arg-Gly-Asp-Ser-Pro-Cys Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
206010035226 Plasma cell myeloma Diseases 0.000 description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
239000012149 elution buffer Substances 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
201000000050 myeloid neoplasm Diseases 0.000 description 6
229920002401 polyacrylamide Polymers 0.000 description 6
239000007787 solid Substances 0.000 description 6
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
239000004793 Polystyrene Substances 0.000 description 5
239000013592 cell lysate Substances 0.000 description 5
239000011536 extraction buffer Substances 0.000 description 5
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
229920002223 polystyrene Polymers 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
239000000725 suspension Substances 0.000 description 5
-1 temperature Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
210000004881 tumor cell Anatomy 0.000 description 5
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
108010067306 Fibronectins Proteins 0.000 description 4
102000016359 Fibronectins Human genes 0.000 description 4
239000004366 Glucose oxidase Substances 0.000 description 4
108010015776 Glucose oxidase Proteins 0.000 description 4
101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 4
108010001336 Horseradish Peroxidase Proteins 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
230000021164 cell adhesion Effects 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
238000010828 elution Methods 0.000 description 4
229940116332 glucose oxidase Drugs 0.000 description 4
235000019420 glucose oxidase Nutrition 0.000 description 4
108010044896 glycyl-arginyl-glycyl-glutamyl-seryl-proline Proteins 0.000 description 4
230000008105 immune reaction Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
238000010814 radioimmunoprecipitation assay Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
150000003839 salts Chemical group 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
210000004988 splenocyte Anatomy 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
210000003606 umbilical vein Anatomy 0.000 description 4
NTEDOEBWPRVVSG-XUXIUFHCSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(O)=O NTEDOEBWPRVVSG-XUXIUFHCSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
206010003445 Ascites Diseases 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000007547 Laminin Human genes 0.000 description 3
108010085895 Laminin Proteins 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
102220516735 Protease-associated domain-containing protein 1_M16A_mutation Human genes 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
210000003038 endothelium Anatomy 0.000 description 3
239000011521 glass Substances 0.000 description 3
108010064365 glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine Proteins 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000010185 immunofluorescence analysis Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
239000013642 negative control Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
239000002356 single layer Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
AGOOUZZBQZNYCU-AJNGGQMLSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(O)=O AGOOUZZBQZNYCU-AJNGGQMLSA-N 0.000 description 2
OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108010042918 Integrin alpha5beta1 Proteins 0.000 description 2
102000008607 Integrin beta3 Human genes 0.000 description 2
108010020950 Integrin beta3 Proteins 0.000 description 2
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930195722 L-methionine Natural products 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 2
108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000003277 amino acid sequence analysis Methods 0.000 description 2
230000003321 amplification Effects 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
230000007910 cell fusion Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229940009976 deoxycholate Drugs 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000000975 dye Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000000464 low-speed centrifugation Methods 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000004264 monolayer culture Methods 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
238000004114 suspension culture Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
ZRVZOBGMZWVJOS-VMXHOPILSA-N (2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN ZRVZOBGMZWVJOS-VMXHOPILSA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
238000011729 BALB/c nude mouse Methods 0.000 description 1
244000180534 Berberis hybrid Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000003846 Carbonic anhydrases Human genes 0.000 description 1
108090000209 Carbonic anhydrases Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000012432 Collagen Type V Human genes 0.000 description 1
108010022514 Collagen Type V Proteins 0.000 description 1
102000000989 Complement System Proteins Human genes 0.000 description 1
108010069112 Complement System Proteins Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
101000803709 Homo sapiens Vitronectin Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
244000131360 Morinda citrifolia Species 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
108010065081 Phosphorylase b Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000011116 calcium hydroxide Nutrition 0.000 description 1
238000003352 cell adhesion assay Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
210000000624 ear auricle Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
235000014413 iron hydroxide Nutrition 0.000 description 1
NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical class [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
235000017524 noni Nutrition 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000379 polypropylene carbonate Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000011118 potassium hydroxide Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000011121 sodium hydroxide Nutrition 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Landscapes

Peptides Or Proteins (AREA)

NO89892941A 1987-11-19 1989-07-18 Monoklonalt antistoff mot den rgd-rettede adhesjonsreseptor paa endotelceller. NO892941L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12304587A	1987-11-19	1987-11-19
PCT/US1988/004118 WO1989005155A1 (en)	1987-11-19	1988-11-17	Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells

Publications (2)

Publication Number	Publication Date
NO892941D0 NO892941D0 (no)	1989-07-18
NO892941L true NO892941L (no)	1989-09-15

Family

ID=26778066

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO89892941A NO892941L (no)	1987-11-19	1989-07-18	Monoklonalt antistoff mot den rgd-rettede adhesjonsreseptor paa endotelceller.

Country Status (2)

Country	Link
DK (1)	DK355589A (da)
NO (1)	NO892941L (da)

1989
- 1989-07-18 DK DK355589A patent/DK355589A/da not_active Application Discontinuation
- 1989-07-18 NO NO89892941A patent/NO892941L/no unknown

Also Published As

Publication number	Publication date
NO892941D0 (no)	1989-07-18
DK355589A (da)	1989-09-18
DK355589D0 (da)	1989-07-18

Publication	Publication Date	Title
US5284751A (en)	1994-02-08	Antibodies that bind to a ligand-induced binding site on GPIIIa
US5306620A (en)	1994-04-26	Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
US5196511A (en)	1993-03-23	Peptides and antibodies that inhibit integrin-ligand binding
US5204445A (en)	1993-04-20	Peptides and antibodies that inhibit integrin-ligand binding
US5262520A (en)	1993-11-16	Peptides and antibodies that inhibit integrin-ligand binding
US5919754A (en)	1999-07-06	Method of inhibiting fibrinogen binding to endothelial cells with fibrinogen gamma chain peptides
US5473051A (en)	1995-12-05	Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs
EP0341303A1 (en)	1989-11-15	Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells
Daviet et al.	1995	A Structural/Functional Domain on Human CD36 Is Involved in the Binding of Anti-Nakα Antibodies
NO892941L (no)	1989-09-15	Monoklonalt antistoff mot den rgd-rettede adhesjonsreseptor paa endotelceller.
EP0524737A2 (en)	1993-01-27	Protein s. polypeptides and anti-peptide antibodies that inhibit protein s binding TO C4b binding protein, diagnostic systems and therapeutic methods
US20020177173A1 (en)	2002-11-28	In vitro methods for determining in vivo thrombotic events
AU675073B2 (en)	1997-01-23	Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation
AU622117B2 (en)	1992-04-02	Peptides and antibodies that inhibit platelet adhesion